Aasim Sheikh

7.5k total citations
27 papers, 957 citations indexed

About

Aasim Sheikh is a scholar working on Epidemiology, Hepatology and Oncology. According to data from OpenAlex, Aasim Sheikh has authored 27 papers receiving a total of 957 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Epidemiology, 19 papers in Hepatology and 5 papers in Oncology. Recurrent topics in Aasim Sheikh's work include Liver Disease Diagnosis and Treatment (15 papers), Hepatitis C virus research (13 papers) and Drug Transport and Resistance Mechanisms (5 papers). Aasim Sheikh is often cited by papers focused on Liver Disease Diagnosis and Treatment (15 papers), Hepatitis C virus research (13 papers) and Drug Transport and Resistance Mechanisms (5 papers). Aasim Sheikh collaborates with scholars based in United States, Canada and United Kingdom. Aasim Sheikh's co-authors include Zeid Kayali, Eric Lawitz, Bradley Freilich, Edward Lebovics, Harold W. Horowitz, Zachary Goodman, David C. Wolf, R. M. Goldberg, Edward Mena and Kris V. Kowdley and has published in prestigious journals such as Gastroenterology, Hepatology and Journal of Hepatology.

In The Last Decade

Aasim Sheikh

27 papers receiving 934 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aasim Sheikh United States 15 724 553 155 134 124 27 957
Il Han Song South Korea 16 354 0.5× 418 0.8× 51 0.3× 181 1.4× 31 0.3× 54 791
Nicholas Taylor United Kingdom 15 433 0.6× 442 0.8× 36 0.2× 201 1.5× 19 0.2× 38 839
Rebecca Cable United States 11 468 0.6× 318 0.6× 48 0.3× 85 0.6× 123 1.0× 20 591
Gabriella Di Lorenzo Italy 12 396 0.5× 351 0.6× 144 0.9× 84 0.6× 22 0.2× 14 751
Madunil Anuk Niriella Sri Lanka 14 382 0.5× 199 0.4× 57 0.4× 128 1.0× 144 1.2× 85 650
Karen F. Murray United States 15 678 0.9× 595 1.1× 48 0.3× 72 0.5× 61 0.5× 38 855
Liane Rabinowich Israel 13 202 0.3× 141 0.3× 484 3.1× 98 0.7× 40 0.3× 25 819
Virginia Nguyen United States 10 331 0.5× 125 0.2× 19 0.1× 171 1.3× 93 0.8× 14 774
Zahra Younoszai United States 16 1.5k 2.1× 955 1.7× 34 0.2× 206 1.5× 490 4.0× 32 1.7k
Włodzimierz Mazur Poland 14 532 0.7× 374 0.7× 71 0.5× 41 0.3× 21 0.2× 61 681

Countries citing papers authored by Aasim Sheikh

Since Specialization
Citations

This map shows the geographic impact of Aasim Sheikh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aasim Sheikh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aasim Sheikh more than expected).

Fields of papers citing papers by Aasim Sheikh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aasim Sheikh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aasim Sheikh. The network helps show where Aasim Sheikh may publish in the future.

Co-authorship network of co-authors of Aasim Sheikh

This figure shows the co-authorship network connecting the top 25 collaborators of Aasim Sheikh. A scholar is included among the top collaborators of Aasim Sheikh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aasim Sheikh. Aasim Sheikh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hart, Phil A., Raj J. Shah, José Nieto, et al.. (2023). A Randomized Controlled Phase 2 Dose-Finding Trial to Evaluate the Efficacy and Safety of Camostat in the Treatment of Painful Chronic Pancreatitis: The TACTIC Study. Gastroenterology. 166(4). 658–666.e6. 9 indexed citations
2.
Ratziu, Vlad, Mary E. Rinella, Brent A. Neuschwander‐Tetri, et al.. (2021). EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. Journal of Hepatology. 76(3). 506–517. 87 indexed citations
3.
Younossi, Zobair M., Maria Stepanova, Mazen Noureddin, et al.. (2021). Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. Hepatology Communications. 5(7). 1201–1211. 24 indexed citations
4.
Vuppalanchi, Raj, Stephen H. Caldwell, Nikolaos Pyrsopoulos, et al.. (2021). Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis. Journal of Hepatology. 76(1). 75–85. 50 indexed citations
5.
Newsome, Philip N., Melissa Palmer, Bradley Freilich, et al.. (2020). Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study. Journal of Hepatology. 73(2). 231–240. 65 indexed citations
6.
Harrison, Stephen A., Zachary Goodman, Abdul Jabbar, et al.. (2019). A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. Journal of Hepatology. 72(5). 816–827. 188 indexed citations
7.
8.
Kuria, Mary Wangari, et al.. (2018). Maternal depression and child severe acute malnutrition: a case-control study from Kenya. BMC Pediatrics. 18(1). 289–289. 26 indexed citations
9.
Shiffman, Mitchell L., Mark Sulkowski, Graham R. Foster, et al.. (2017). Safety and Efficacy of Sofosbuvir/Velpatasvir for the Treatment of Chronic Hepatitis C in Patients Aged 65 Years or Older: A Retrospective Analysis of Phase 3 Studies. Gastroenterology. 152(5). S1097–S1097. 2 indexed citations
10.
Kowdley, Kris V., Daniel Nelson, Jacob Lalezari, et al.. (2015). P0829 : On-treatment HCVRNA as a predictor of sustained virologic response in HCV genotype 3 infected patients treated with daclatasvir and sofosbuvir: analysis of phase 3 ALLY-3 study. Journal of Hepatology. 62. S648–S648. 2 indexed citations
11.
Lawitz, Eric, Edwin DeJesus, Eric M. Yoshida, et al.. (2015). Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2). Hepatology. 64(2). 360–369. 142 indexed citations
12.
13.
Kowdley, Kris V., David R. Nelson, Jacob Lalezari, et al.. (2015). Tu1013 On-Treatment HCV RNA As a Predictor of Sustained Virologie Response in HCV Genotype 3 - Infected Patients Treated With Daclatasvir and Sofosbuvir: Analysis of Phase 3 Ally-3 Study. Gastroenterology. 148(4). S–1084. 1 indexed citations
14.
Läwitz, E., M. Rodríguez‐Torres, Tuyet Thi Nguyen, et al.. (2014). P1222 A PHASE II STUDY OF SAMATASVIR (IDX719) IN COMBINATION WITH SIMEPREVIR AND RIBAVIRIN IN TREATMENT-NAÏVE HCV-INFECTED SUBJECTS WITH GENOTYPES 1B AND 4 (HELIX-1 STUDY). Journal of Hepatology. 60(1). S495–S496. 7 indexed citations
15.
Rodríguez‐Torres, M., E. Läwitz, Barbara R. Conway, et al.. (2010). 31 SAFETY AND ANTIVIRAL ACTIVITY OF THE HCV NON-NUCLEOSIDE POLYMERASE INHIBITOR VX-222 IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS. Journal of Hepatology. 52. S14–S14. 26 indexed citations
16.
McHutchison, John G., Gregory T. Everson, Ira M. Jacobson, et al.. (2010). 277 GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN IMPROVES BIOPSY NECRO-INFLAMMATORY SCORES AND ALT NORMALIZATION AT 48 WEEKS VERSUS PEG-IFN/RIBAVIRIN IN GENOTYPE 1 CHRONIC HCV PATIENTS. Journal of Hepatology. 52. S116–S116. 3 indexed citations
17.
Läwitz, E., Curtis Cooper, M. Rodríguez‐Torres, et al.. (2009). 92 SAFETY, TOLERABILITY AND ANTIVIRAL ACTIVITY OF VCH-916, A NOVEL NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION. Journal of Hepatology. 50. S37–S37. 22 indexed citations
18.
Arguedas, Miguel R., et al.. (2007). Assessment of the PHQ-9 as a Screening Tool for Depression in Patients with Chronic Hepatitis C. Digestive Diseases and Sciences. 53(4). 1100–1106. 35 indexed citations
19.
Sheikh, Aasim, David C. Wolf, Edward Lebovics, R. M. Goldberg, & Harold W. Horowitz. (1999). CONCOMITANT HUMAN IMMUNODEFICIENCY VIRUS PROTEASE INHIBITOR THERAPY MARKEDLY REDUCES TACROLIMUS METABOLISM AND INCREASES BLOOD LEVELS. Transplantation. 68(2). 307–309. 70 indexed citations
20.
Sheikh, Aasim, et al.. (1998). Early ERCP in the management of acute biliary pancreatitis: A meta-analysis. Gastroenterology. 114. A497–A497. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Il Han Song Breakdown of academic impact, for papers by Nicholas Taylor Breakdown of academic impact, for papers by Rebecca Cable Breakdown of academic impact, for papers by Gabriella Di Lorenzo Breakdown of academic impact, for papers by Madunil Anuk Niriella Breakdown of academic impact, for papers by Karen F. Murray Breakdown of academic impact, for papers by Liane Rabinowich Breakdown of academic impact, for papers by Virginia Nguyen Breakdown of academic impact, for papers by Zahra Younoszai Breakdown of academic impact, for papers by Włodzimierz Mazur
Rankless by CCL
2026